Closing date of IPO - Friday, 4 November2022/11/02 09:00:00
Download PDF Stock report
Closing date of IPO - Friday, 4 November CILO CYBIN HOLDINGS LIMITED (Incorporated in South Africa) (Registration number 2022/320351/06) Ordinary Shares Share code: CCC ISIN: ZAE000310397 (“the Company”) CLOSING DATE OF IPO – FRIDAY, 4 NOVEMBER 2022 Further to the Exchange News Service of the JSE Limited announcement on 12 September where Cilo Cybin Holdings Limited informed the market of its intention to raise a Minimum Amount of R500 million by means of an IPO and list on the JSE main board, the Company would like to remind interested investors of the dates as set out in the Prospectus. Cilo Cybin Holdings Limited was incorporated by the Founder, Gabriel Theron, for the purposes of being listed on the Main Board of the JSE with effect from the commencement of trade on Monday, 14 November 2022, as a special purpose acquisition company to pursue acquisitions of, and investments in, commercial enterprises operating in the Biotech, Biohacking or Pharmaceutical sector that will enable it to develop and expand methodologies by utilising Artificial Intelligence (AI) and expertise of medical specialists to deliver holistic and individualised solutions to customers to better their health, performance and increase their longevity. The Prospectus and other supporting documentation are available on the website. The industries Cilo Cybin envisions to participate in include Biotech, Cannabis, Psychedelics, wearable devices and custom nutrition. The Company has identified potential opportunities to acquire several assets located in South Africa and United States of America (which are still subject to shareholder approval). One of these assets are Cilo Cybin Pharmaceutical Proprietary Limited (“CCP”). Gabriel Theron is also the founder and main shareholder in CCP. CCP has a state-of-the-art cultivation, manufacturing and packaging facility in Midrand. The vision of the Company, from the outset, was not to sell cannabis flower, as a final product but rather processed pharmaceutical grade products. CCP holds a GACP license from the regulator in South Africa, SAHPRA to cultivate cannabis and a second license for the manufacturing of an Active Pharmaceutical Ingredient (API) oil and to manufacture final labelled pharmaceutical grade product, making CCP the first Company in South Africa to have both GACP and GMP cannabis licenses in one Company. CCP not only develops, manufactures and distributes its own branded products but also manufactures pharmaceutical grade products for local and international third parties on a tolling basis. Globally cannabis, psychedelics and overall physical and mental health have become high growth, high margin, attractive businesses to invest in. CCP has been operating in this sector since 2018 (for 4 years) formulating and producing its own branded product and are leaders in this market segment. DATES AND TIMES FOR IPO 2022 Opening date of the IPO (09h00) Monday, 12 September Closing date of the IPO (12h00) Friday, 4 November Finalisation Results of the IPO released on SENS Tuesday, 8 November Notification of allotments to successful investors by Tuesday, 8 November Finalisation Results of the IPO published in the press on Wednesday, 9 November Proposed date of Listing (09h00) Monday, 14 November To register an interest in the IPO and to receive IPO related documentation send an email to email@example.com or visit www.cilocybin.com Midrand 2 November 2022 Sponsor DEA-RU Proprietary Limited Date: 02-11-2022 09:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.